ClinicalTrials.gg
CompletedNCT01895322Updated Jan 1, 2016Results posted

Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis

A Phase 2 interventional study of OPC-41061 in Chronic Renal Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 6 sites in Japan. Per ClinicalTrials.gov, last updated 2016-01-01.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Kidney Failure, Chronic with a site in Japan — 1 open to participants now, 3 under way, 2 of them phase 3. Kidney Failure, Chronic · Japan.

Enrollment
20th of 24
20 · median 127
Started
2013
with 6 others
Phase 2
7 of 30
none open now
Registered
18th of 30
by date
Lead sponsor
3 of 30
Otsuka Pharmaceutical Co., Ltd.

Among the 30 studies in Kidney Failure, Chronic with a site in Japan, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2013, is one of 7 in phase 2, and was the 18th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

1 of the 30 studies in Kidney Failure, Chronic with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Kidney Failure, Chronic with a site in Japan, or all of them as a file.
02

Study summary

To investigate the efficacy, pharmacokinetics, pharmacodynamics, and safety of OPC-41061 in patients with chronic renal failure who are undergoing peritoneal dialysis, using daily urine volume, body weight, and edematous conditions as parameters and conducting dose escalation every 2 days until reaching the dose that achieves urine volume increase and then performing 5-day repeated administration at the fixed dose, the final dose used in the dose escalation period.

03

Conditions studied

  • Chronic Renal Failure

Keywords

  • Tolvaptan
  • dialysis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with chronic renal failure
  • Patients who are undergoing peritoneal dialysis (continuous ambulatory peritoneal dialysis [CAPD])
  • Patients who, after undergoing peritoneal dialysis, received any of the following medical treatments for fluid overload [OR: hypervolemia] that had insufficient effect:

    • Addition or increase of diuretics
    • Increase in concentration or volume of peritoneal dialysis fluid
    • Increase in the number of changes of peritoneal dialysis fluid
  • Subjects who, together with their partner, are able to practice one of the specified methods until 4 weeks after the final trial drug administration
  • Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial period

Exclusion criteria

Exclusion Criteria:

  • Subjects with any of the following diseases, complications, or symptoms:

    • Suspected hypovolemia
    • Daily urine volume less than 200 mL
    • Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
    • Cardiac function of class 4
  • Subjects with any of the following medical histories:

    • History of cerebrovascular disorder or coronary artery disease within 4 weeks prior to
    • History of or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
  • Subjects with any of the following abnormal laboratory values:

lower than 9.0 g/dL, total higher than 3.0 g/dL, (GPT) or AST (GOT) 2 times the upper limit of the reference range of the trial site, serum sodium higher than the upper limit of the reference range of the trial site, serum sodium lower than 125 mEq/L, or serum potassium higher than 5.5 mEq/L

  • Subjects with any of the following conditions, concomitant diseases, or symptoms:

    • defect in diaphragm
    • hemorrhagic diathesis due to uremia
    • suspected lactic acid metabolic disorder
    • suspected peritonitis, peritoneal damage, peritoneal adhesion, or disorders in intraabdominal organs
  • Subjects who have undergone peritoneal dialysis for 8 years or longer
  • Subjects who are scheduled to undergo hemodialysis or concomitant use of hemodialysis, or renal transplantation
  • Subjects who have participated in any other clinical trial or post-marketing clinical studies within 30 days prior to informed consent
  • Subjects who have previously received OPC-41061
  • Subjects who are unable to sense thirst or who have difficulty with fluid or food intake
  • Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period
  • Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    OPC-41061

    Drug: OPC-41061

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Daily Urine Volume From Baseline

    Change in daily urine volume from baseline during the repeated-administration period (For five days).

    Time frame: Urine Volume on day13 minus Urine Volume at baseline(day9) on the repeated-administration period.

  2. Percent Change in Daily Urine Volume From Baseline

    Percent change in daily urine volume from baseline during the repeated-administration period (For five days).

    Time frame: 100%*<Urine Volume on day13 minus Urine Volume at baseline(day9) on the repeated-administration period/Urine Volume at baseline(day9) on the repeated-administration period>

Secondary outcomes

  1. Change in Body Weight From Baseline

    Change in body weight from baseline during the repeated-administration period(For five days).

    Time frame: Body weight on day13 minus Body weight at baseline(day9) on the repeated-administration period

  2. Percent Change in Body Weight

    Percent change in body weight from baseline during the repeated-administration period(For five days).

    Time frame: 100%*<Body weight on day13 minus Body weight at baseline (day9)/Body weight at baseline(day9)>

07

Results

Posted Jan 1, 2016

Participant flow

Participant flow — Overall Study
MilestoneOPC-41061
Started20
Completed7
Not completed13
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation10

Outcome measures

PrimaryChange in Daily Urine Volume From Baseline

Change in daily urine volume from baseline during the repeated-administration period (For five days).

Time frame:
Urine Volume on day13 minus Urine Volume at baseline(day9) on the repeated-administration period.
Reported as:
Mean · mL
Change in Daily Urine Volume From Baseline
mLOPC-41061
Change in Daily Urine Volume From Baseline18.3 ± 340.2
SecondaryChange in Body Weight From Baseline

Change in body weight from baseline during the repeated-administration period(For five days).

Time frame:
Body weight on day13 minus Body weight at baseline(day9) on the repeated-administration period
Reported as:
Mean · kg
Change in Body Weight From Baseline
kgOPC-41061
Change in Body Weight From Baseline-0.61 ± 0.84
PrimaryPercent Change in Daily Urine Volume From Baseline

Percent change in daily urine volume from baseline during the repeated-administration period (For five days).

Time frame:
100%*<Urine Volume on day13 minus Urine Volume at baseline(day9) on the repeated-administration period/Urine Volume at baseline(day9) on the repeated-administration period>
Reported as:
Mean · Percentage
Percent Change in Daily Urine Volume From Baseline
PercentageOPC-41061
Percent Change in Daily Urine Volume From Baseline8.89 ± 33.2
SecondaryPercent Change in Body Weight

Percent change in body weight from baseline during the repeated-administration period(For five days).

Time frame:
100%*<Body weight on day13 minus Body weight at baseline (day9)/Body weight at baseline(day9)>
Reported as:
Mean · Percentage
Percent Change in Body Weight
PercentageOPC-41061
Percent Change in Body Weight-0.92 ± 1.31

Adverse events

Collected over daily for 13 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-41061—0/20 (0%)13/20 (65%)
Most frequent other events
Most frequent other events
EventOPC-41061
ConstipationGastrointestinal disorders4/20
Blood sodium decreasedInvestigations4/20
Nephrogenic anaemiaBlood and lymphatic system disorders3/20
ThirstGeneral disorders3/20
NasopharyngitisInfections and infestations2/20
HyponatraemiaMetabolism and nutrition disorders2/20
PruritusSkin and subcutaneous tissue disorders2/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OPC-41061
<=18 years0
Between 18 and 65 years8
>=65 years12
Age, Continuous
Age, Continuous(years)OPC-41061
Mean65.1 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061
Female12
Male8
Region of Enrollment
Region of Enrollment(participants)OPC-41061
Japan20
08

Study locations

6 sites
  • Chubu Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Feb 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2013
First posted
Jul 10, 2013
Start
Jul 2013
Primary completionActual
Feb 2014
CompletionActual
Aug 2014
Results first posted
Jan 1, 2016
Last update
Jan 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01895322
Responsible party
Sponsor
First posted
Jul 10, 2013
Start date
Jul 2013
Primary completion
Feb 2014
Completion
Aug 2014
Results posted
Jan 1, 2016
Last update
Jan 1, 2016

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion